End-of-day quote
Shenzhen S.E.
06:00:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
3.67
CNY
|
+2.51%
|
|
+10.21%
|
-18.81%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
6,840
|
7,758
|
11,975
|
6,811
|
5,540
|
5,864
|
Enterprise Value (EV)
1 |
8,452
|
7,945
|
13,262
|
9,617
|
8,617
|
5,864
|
P/E ratio
|
56.9
x
|
-49.8
x
|
-20.6
x
|
-4.38
x
|
527
x
|
-55.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.77
x
|
3.17
x
|
5.44
x
|
3.31
x
|
3.11
x
|
3.97
x
|
EV / Revenue
|
3.42
x
|
3.25
x
|
6.03
x
|
4.67
x
|
4.84
x
|
3.97
x
|
EV / EBITDA
|
24.1
x
|
-30.3
x
|
-39.8
x
|
-18.4
x
|
350
x
|
42.2
x
|
EV / FCF
|
-7.78
x
|
11.6
x
|
-10.8
x
|
-10.6
x
|
-18.5
x
|
-
|
FCF Yield
|
-12.9%
|
8.61%
|
-9.28%
|
-9.4%
|
-5.41%
|
-
|
Price to Book
|
1.48
x
|
1.74
x
|
3.23
x
|
3.17
x
|
2.56
x
|
-
|
Nbr of stocks (in thousands)
|
1,335,979
|
1,297,365
|
1,297,365
|
1,297,365
|
1,297,365
|
1,297,365
|
Reference price
2 |
5.120
|
5.980
|
9.230
|
5.250
|
4.270
|
4.520
|
Announcement Date
|
4/25/19
|
4/29/20
|
4/26/21
|
4/26/22
|
4/10/23
|
4/26/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
2,472
|
2,445
|
2,200
|
2,059
|
1,779
|
1,479
|
EBITDA
1 |
351.4
|
-261.8
|
-333.3
|
-521.3
|
24.6
|
138.9
|
EBIT
1 |
236.2
|
-392.3
|
-641.3
|
-697.3
|
-127.8
|
-18.58
|
Operating Margin
|
9.55%
|
-16.04%
|
-29.15%
|
-33.86%
|
-7.18%
|
-1.26%
|
Earnings before Tax (EBT)
1 |
143.1
|
-123.2
|
-712.2
|
-1,556
|
-58.9
|
-118.6
|
Net income
1 |
119.6
|
-159.1
|
-580.2
|
-1,555
|
10.52
|
-106.5
|
Net margin
|
4.84%
|
-6.51%
|
-26.37%
|
-75.54%
|
0.59%
|
-7.2%
|
EPS
2 |
0.0900
|
-0.1200
|
-0.4472
|
-1.199
|
0.008100
|
-0.0821
|
Free Cash Flow
1 |
-1,086
|
684.2
|
-1,231
|
-904.4
|
-465.7
|
-
|
FCF margin
|
-43.95%
|
27.98%
|
-55.95%
|
-43.92%
|
-26.18%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/25/19
|
4/29/20
|
4/26/21
|
4/26/22
|
4/10/23
|
4/26/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
1,612
|
187
|
1,287
|
2,806
|
3,077
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
4.587
x
|
-0.7126
x
|
-3.862
x
|
-5.383
x
|
125.1
x
|
-
|
Free Cash Flow
1 |
-1,086
|
684
|
-1,231
|
-904
|
-466
|
-
|
ROE (net income / shareholders' equity)
|
2.07%
|
-4.12%
|
-15.2%
|
-50.3%
|
0.1%
|
-5.85%
|
ROA (Net income/ Total Assets)
|
1.41%
|
-2.32%
|
-3.81%
|
-4.68%
|
-1.02%
|
-
|
Assets
1 |
8,458
|
6,852
|
15,240
|
33,267
|
-1,035
|
-
|
Book Value Per Share
2 |
3.450
|
3.440
|
2.860
|
1.660
|
1.670
|
-
|
Cash Flow per Share
2 |
1.970
|
1.610
|
0.9700
|
0.5800
|
0.3000
|
-
|
Capex
1 |
565
|
468
|
769
|
415
|
264
|
211
|
Capex / Sales
|
22.86%
|
19.14%
|
34.94%
|
20.16%
|
14.83%
|
14.25%
|
Announcement Date
|
4/25/19
|
4/29/20
|
4/26/21
|
4/26/22
|
4/10/23
|
4/26/24
|
|
1st Jan change
|
Capi.
|
---|
| -18.81% | 658M | | +33.25% | 704B | | +28.59% | 577B | | -3.55% | 348B | | +18.16% | 327B | | +4.36% | 288B | | +14.81% | 234B | | +4.93% | 198B | | -9.78% | 194B | | -3.69% | 147B |
Other Pharmaceuticals
|